Speed to market wont guarantee success in todays launch environment. Anticipating what prescribers, patients and payers will ...

With the wrong architecture in place, AI algorithms can nudge biopharmaceutical developers toward unpredicted and misaligned ...

Sometimes it’s difficult to separate the identity of a company from that of its CEO. For example, when we think of Amazon and Microsoft, we naturally think of Jeff Bezos and Bill Gates. In the ...

Spinning off a $4 billion biopharma business is no easy task. Integrated functions need to be separated, governance boards created, leadership teams assembled, and corporate headquarters established.

In the rapidly evolving world of life sciences, companies are constantly seeking ways to optimize their business structures to better navigate the complex landscape of drug development and financing.

New York City-based Volastra Therapeutics – whose founders and scientific advisors are leading chromosomal instability researchers and experts – have in four years’ time advanced two drug candidates ...

As the fentanyl epidemic rages on, opioid antagonist rescue agents like Narcan, Kloxxado, and Opvee have become omnipresent. Like defibrillators and EpiPens, advocates insist they should be available ...

“THAT WAS A TERRIFYING MOMENT,” reflects Matt Patterson, cofounder, chairman, and CEO of Audentes Therapeutics, a genetic medicines company focused on the adeno-associated virus (AAV). It was the fall ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

Royalty-bearing license agreements are a cornerstone of commercialization in the life sciences and technology industries. Companies often use them to expand their business into new markets while ...

Continuous improvement doesn’t just depend upon Lean principles and/or zero-based budgeting. It depends upon people inspired by a culture that values learning, promotes problem-solving skills, and ...

No drug is free from risks, and no two human anatomies are completely identical (meaning different individuals can face different risks), but from a real-world patient perspective — anecdotally — the ...